Thomas Emm

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

Jack Shi, Xuejun Chen, Fiona Lee et al. · The Journal of Clinical Pharmacology · 2014 · 223 citations

Immunology, Pharmacotherapy, Inflammatory Arthritis +18

The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers

Jack Shi, Xuejun Chen, Ryan McGee et al. · The Journal of Clinical Pharmacology · 2011 · 164 citations

Jak Enzymes, Incb018424 Phosphate, Medicine +8

The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers

Jack Shi, Xuejun Chen, Thomas Emm et al. · The Journal of Clinical Pharmacology · 2011 · 111 citations

Incb018424 Phosphate, Chemoprevention Strategy, Immunology +18

Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans

Adam D. Shilling, Frank M. Nedza, Thomas Emm et al. · Drug Metabolism and Disposition · 2010 · 107 citations

Potent Benzimidazole Sulfonamide Protein Tyrosine Phosphatase 1B Inhibitors Containing the Heterocyclic ( <i>S</i> )-Isothiazolidinone Phosphotyrosine Mimetic

Andrew P. Combs, Wenyu Zhu, Matthew L. Crawley et al. · Journal of Medicinal Chemistry · 2006 · 85 citations · Full text